secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2021-12-10T23:59:59+00:00
Accession:  0001698530-21-000107
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure to cut 50% workforce, wind down two programs, repay $10M debt after data misconduct investigation
--------------------------------------------------------------------------------

- Exicure entered Amendment No. 4 with MidCap to prepay $10.0M of its senior secured term loan, leaving $7.5M outstanding, and placed $8.0M in a blocked account.
- Company to wind down cavrotolimod (AST-008) and XCUR-FXN programs, cutting ~50% of workforce by Jan 2022 with $1.2M in severance costs.
- Brian C. Bock appointed CEO and board member, replacing David Giljohann who becomes CTO through Jan 2022; Matthias Schroff named CSO; Douglas Feltner to depart.
- Internal investigation found former researcher Grant Corbett misreported XCUR-FXN efficacy data from autumn 2020 to Feb 2021, acting alone; no material financial impact.
- Company expects ~$6.0M in employee cost savings in 2022 from restructuring, and will focus on SCN9A pain program and partnered programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853021000107/0001698530-21-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853021000107/xcur-20211210.htm
  HTML page:      https://secwatch.observer/filing/0001698530-21-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer